Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Sonnet BioTherapeutics (NASDAQ: SONN) has released its latest CEO Corner segment featuring CEO Pankaj Mohan, Ph.D. The segment, published on the company's website, reviews key accomplishments for 2024 and outlines targeted value-driving milestones for 2025. The content will remain accessible on www.sonnetbio.com for 90 days.
Sonnet BioTherapeutics (NASDAQ: SONN) ha pubblicato il suo ultimo segmento CEO Corner con il CEO Pankaj Mohan, Ph.D. Il segmento, pubblicato sul sito web dell'azienda, rivede i risultati chiave per il 2024 e delinea traguardi mirati per il valore nel 2025. Il contenuto rimarrà accessibile su www.sonnetbio.com per 90 giorni.
Sonnet BioTherapeutics (NASDAQ: SONN) ha lanzado su último segmento CEO Corner con el CEO Pankaj Mohan, Ph.D. Este segmento, publicado en el sitio web de la empresa, revisa los logros clave para 2024 y esboza hitos orientados al valor para 2025. El contenido permanecerá accesible en www.sonnetbio.com durante 90 días.
Sonnet BioTherapeutics (NASDAQ: SONN)는 CEO Pankaj Mohan 박사가 출연하는 최신 CEO Corner 세그먼트를 발표했습니다. 회사 웹사이트에 게시된 이 세그먼트에서는 2024년의 주요 성과를 검토하고 2025년의 가치 창출 목표를 설명합니다. 이 콘텐츠는 www.sonnetbio.com에서 90일 동안 접근 가능합니다.
Sonnet BioTherapeutics (NASDAQ: SONN) a publié son dernier segment CEO Corner avec le PDG Pankaj Mohan, Ph.D. Le segment, publié sur le site de l'entreprise, passe en revue les réalisations clés pour 2024 et décrit les jalons ciblés créateurs de valeur pour 2025. Le contenu restera accessible sur www.sonnetbio.com pendant 90 jours.
Sonnet BioTherapeutics (NASDAQ: SONN) hat sein neuestes CEO Corner Segment mit CEO Pankaj Mohan, Ph.D. veröffentlicht. Das Segment, das auf der Unternehmenswebsite veröffentlicht wurde, überprüft wichtige Leistungen für 2024 und skizziert zielgerichtete wertschöpfende Meilensteine für 2025. Der Inhalt bleibt 90 Tage lang auf www.sonnetbio.com zugänglich.
- None.
- None.
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.
As part of the CEO Corner segment, Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet, highlighted the Company’s key accomplishments for calendar year 2024 and the targeted value-driving milestones in calendar year 2025.
The CEO Corner is now accessible on the Company’s website here. Segments on the CEO Corner platform will be accessible on the Company’s website (www.sonnetbio.com) for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
SONN@jtcir.com
FAQ
What did Sonnet BioTherapeutics (SONN) announce in their December 23, 2024 update?
How long will the December 2024 CEO Corner segment be available on Sonnet's website?
What topics does the SONN CEO Corner segment cover in December 2024?
Who presents the December 2024 CEO Corner update for Sonnet BioTherapeutics (SONN)?
